These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 23965805)

  • 1. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
    Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
    Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
    McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
    J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
    Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
    Ryttberg L; Diamantopoulos A; Forster F; Lees M; Fraschke A; Björholt I
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):601-15. PubMed ID: 21958104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
    Plumb JM; Clemens A; Monz BU
    Pharmacoeconomics; 2010; 28(9):781-2; author reply 782-4, 784-5. PubMed ID: 20824908
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
    Kotirum S; Chongmelaxme B; Chaiyakunapruk N
    J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.